# Scientific Committee

#### Nicoletta Colombo

Director, Program Gynecologic Oncology, IEO, Milan

#### Angelo Maggioni

Director, Division of Gynaecology, IEO, Milan

#### Giovanni Aletti

Innovative Therapeutic Strategies in Ovarian Cancer Unit, IEO, Milan

#### Vanna Zanagnolo

Director, Mini-invasive and Robotic Gunecologic Cancer Surgery Unit, IEO, Milan

#### Fedro Peccatori

Director, Procreation and Fertility Unit, IEO, Milan

# **Faculty**

### Roberto Angioli

University Campus BioMedico, Rome (Italu)

# Pierluigi Benedetti Panici

La Sapienza University, Rome (Italy)

#### Roberto Biffi

IEO, Milan (Italy)

#### Cristina Bosetti

Mario Negri Institute, Milan (Italy)

## Nicoletta Cerana

ACTO Onlus, Milan (Italy)

#### Saverio Cinieri

Hospital Antonio Perrino, Brindisi (Italy)

#### Gennaro Cormio

Aldo Moro University, Bari (Milan)

#### Pernilla Dahm-Kähler

Institute of Clinical Sciences, Göteborg (Sweden)

#### De Censi Andrea

E.O. Ospedali Galliera, Genoa (Italy)

#### Andreas du Bois

KEM | Kliniken Essen-Mitte, Essen (Germany)

#### Anna Fagotti

Cattolica University, Rome (Italy)

#### Anna Maria Ferrero

Mauriziano Hospital, Turin (Italy)

#### Robert Fruscio

San Gerardo Hospital, Monza (Italy)

#### Antonio González Martín

Clinica Universidad de Navarra, Madrid (Spain)

# Fabio Landoni

San Gerardo Hospital, Monza (Italy)

#### Jonathan A. Ledermann

Cancer Research UK and UCL Cancer Trials Centre, London (UK)

#### Franco Odicino

ASST Spedali Civili of Brescia (Italy)

#### Sandro Pionata

IRCCS National Cancer Institute
"Fondazione G. Pascale", Naples (Italy)

#### Carmine Pinto

AUSL-IRCCS of Reggio Emilia (Italy)

#### Karl C. Podratz

Mayo Clinic, Rochester (USA)

#### Francesco Raspagliesi

Istituto Nazionale dei Tumori, Milan (Italy)

#### Maria Giovanna Salerno

San Camillo-Forlanini Hospital, Rome (Italy)

#### Enrico Sartori

ASST Spedali Civili of Brescia (Italy)

### Giovanni Scambia

Gemelli University Hospital, Rome (Italy)

### Paolo Scollo

Cannizzaro Hospital, Catania (Italu)

#### Paolo Zola

University of Turin (Milan)



# Meeting venue

Aula Magna Leonardo la Pietra Building 1 European Institute of Oncology Via Ripamonti 435 — 20141 Milano

### Organizing Secretariat

MZ Congressi srl Via C. Farini 81 20159 Milano Tel. 02 66802323 E ieoedu.eventi@ieo.it



#### **Endorsements**









With the unconditional grant of



# IEO OVARIAN CANCER CENTER-OCC 10 YEARS OF ACTIVITY

Delving into known and unknown aspects of advanced ovarian cancer

Scientific Director: Nicoletta Colombo

14 December 2018

Conference target:
Gynecologists, Gynecologists, Oncologists



# Introduction

Ovarian cancer (OC) remains the leading cause of death for gunecologic malignancies in developed countries. Across different studies, the absolute benefit from care at high-volume centers exceeds the benefit from break-through treatments. Numerous studies suggest that the management of OC pts by gynaecologic oncologists in cancer centers results in improved clinical and economic outcomes.

Based on these premises, in 2008 we opened the Ovarian Cancer Center at the European Institute of Oncology (IEO-OCC) mirrowing a similar initiative founded by Robert Bristow at the Johns Hopkins University in Baltimore. The mission of IEO-OCC was to provide a unique example in Italy of clinical care for patients with ovarian cancer. The main principles were a strong collaboration between experts to assure a multidisciplinary approach for research, prevention and treatment of ovarian cancer. The principal objectives were to improve early diagnosis, survival and quality of life of patients with ovarian cancer and simultaneously to increase the opportunities for additional clinical research projects. We also wanted to enhance awareness of ovarian cancer regarding the importance of prevention and the benefits of centralized expert care for advanced cases.

The multidisciplinary approach represents the distinctive element of the IEO-OCC to guarantee the continuity of care in the complex therapeutics journey of ovarian cancer patients.

To commemorate the 10 year anniversary of IEO-OCC we decided to hold a meeting on December 14, 2018, not only to review the main improvements achieved by the scientific community during the past 10 years, but particularly to identify new perspectives and challenges for the future.

The program will include key-note lectures from national and international experts in the field, followed by round tables with invited participants which will allow large time for discussion.

The afternoon will be dedicated to the important issue of centralization of care, with invited international speakers who will tell us about the successful experiences in their countries on this crucial aspect. A "photography" of Italian ovarian cancer patients and where they received their treatment will be instrumental to the following discussion which will see the participation of political authorities, national societies presidents and advocacy group representatives.

The final objective will be to formulate concrete propositions to improve the access to quality care for the majority of patients with ovarian cancer.

# Scientific Programme

Introduction - N. Colombo

Newly diagnosed advanced ovarian cancer: facts, no hype Moderator: G. Aletti

Keunote Lecture:

How many times shall we "shift our mind" in advanced ovarian cancer surgeru?

A. du Bois

10.20 Panel and Floor Discussion

Discussants: P. Benedetti Panici, R. Biffi, A. Fagotti, F. Landoni, F. Raspagliesi The following topics will be discussed:

- Surgical resectability
- Lymphadenectomy
- **ERAS** implementation
- **HIPEC**
- Interval debulking surgery: when

The journey of upfront therapy in ovarian cancer

Moderator: N. Colombo

Keunote Lecture:

Finding the mark to integrate targeted therapies in front line S. Pignata

Panel and Floor Discussion

Discussants: G. Cormio, A. De Censi, R. Fruscio, A. González Martín, F. Peccatori The following topics will be discussed:

- Can we differentiate treatment based on molecular profiling?: BRCA and beyond
- Is Bevacizumab mandatory?
- Patient selection: residual tumor, comorbidity etc
- Too many new clinical trials: how to choose?
- How to include biomarker research?

A new language for ovarian cancer: will platinum sensitivity remain a relevant prognostic factor?

Moderator: Á. González Martín

Contemporary challenges in the treatment of relapsing ovarian cancer: A pill and nothing more, how far are we? J.A. Ledermann

Panel and Floor Discussion

Discussants: R. Angioli, A. du Bois, A.M. Ferrero, F. Odicino The following topics will be discussed:

- The concept of platinum sensitivity: still valid?
- Platinum or non platinum: how to decide?
- Maintenance treatment: which, when and how long
- Chemo-free treatment: a valid option?
- Coming soon new treatment in ovarian cancer

13 Lunch Moderators: A Maggioni, V. Zanagnolo

Keunote Lectures:

Centralization of care in USA - K.C. Podratz Centralization of care in Sweden - P. Dahm Kähler Where do we treat OC in Italu? - C. Bosetti Centralization of Care in Piedmont region - P. Zola

Role of advocacy groups - N. Cerana (ACTO)

Panel and Floor discussion:

SIGO (President and Past President): G.Scambia, P. Scollo SIOG (President and Past President): E. Sartori, G. Salerno AIOM (Treasurer and Past President): S. Cinieri, C. Pinto ACTO: N. Cerana

Political Authorities: TBC

IEO-OCC after 10 years - G. Aletti

Toast

# Online Registration

The attendance to the Conference is free of charge and it is limited to 200 participants.

You can register online by connecting to https://www.ieo.it/it/ FORMAZIONE/IEO-Education/Corsi-e-congressi/, selecting the event of interest and clicking on "online registration".

# CERTIFICATE OF ATTENDANCE AND CME CREDITS

The course will apply to Agenas for providing Italian CME credits for Gynecologists and Oncologists.

The Certificate of attendance will be delivered at the end of the course at the registration desk.